In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these agents in patients with NSCLC and NTRK2 fusion are available. We present a case of a female patient with NTRK2-positive NSCLC with a complete ongoing response on therapy with larotrectinib, suggesting efficacy of first-generation TRK inhibitors also in NTRK2-positive NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601816 | PMC |
| http://dx.doi.org/10.1159/000533572 | DOI Listing |
Publication Analysis
Top Keywords
non-small cell
8
cell lung
8
lung cancer
8
trk inhibitors
8
ntrk2-positive nsclc
8
complete response
4
response larotrectinib
4
larotrectinib ntrk2
4
ntrk2 fusion-positive
4
fusion-positive non-small
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!